The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Magnesium sulfate | The therapeutic efficacy of Pentazocine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Pentazocine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Orphenadrine | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Pramipexole | Pentazocine may increase the sedative activities of Pramipexole. |
| Ropinirole | Pentazocine may increase the sedative activities of Ropinirole. |
| Rotigotine | Pentazocine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine. |
| Sodium oxybate | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | The therapeutic efficacy of Tapentadol can be decreased when used in combination with Pentazocine. |
| Thalidomide | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Pentazocine is combined with Desmopressin. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Pentazocine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Pentazocine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Pentazocine. |
| Methylnaltrexone | Pentazocine may increase the opioid antagonism activities of Methylnaltrexone. |
| Naloxegol | Pentazocine may increase the opioid antagonism activities of Naloxegol. |
| Mirtazapine | Pentazocine may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Pentazocine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Alaproclate. |
| Ethanol | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine. |
| Phentermine | Phentermine may increase the analgesic activities of Pentazocine. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Pentazocine. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Pentazocine. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Pentazocine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Pentazocine. |
| MMDA | MMDA may increase the analgesic activities of Pentazocine. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Pentazocine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine. |
| Tenamfetamine | Tenamfetamine may increase the analgesic activities of Pentazocine. |
| Chlorphentermine | Chlorphentermine may increase the analgesic activities of Pentazocine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may increase the analgesic activities of Pentazocine. |
| Dextroamphetamine | Dextroamphetamine may increase the analgesic activities of Pentazocine. |
| Metamfetamine | Metamfetamine may increase the analgesic activities of Pentazocine. |
| Iofetamine I-123 | Iofetamine I-123 may increase the analgesic activities of Pentazocine. |
| Ritobegron | Ritobegron may increase the analgesic activities of Pentazocine. |
| Mephedrone | Mephedrone may increase the analgesic activities of Pentazocine. |
| Methoxyphenamine | Methoxyphenamine may increase the analgesic activities of Pentazocine. |
| Gepefrine | Gepefrine may increase the analgesic activities of Pentazocine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Pentazocine. |
| Amphetamine | Amphetamine may increase the analgesic activities of Pentazocine. |
| Phendimetrazine | Phendimetrazine may increase the analgesic activities of Pentazocine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine. |
| Chloroprocaine | The risk or severity of CNS depression can be increased when Pentazocine is combined with Chloroprocaine. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Pentazocine. |
| Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione | The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Pentazocine. |
| Agmatine | The risk or severity of adverse effects can be increased when Agmatine is combined with Pentazocine. |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine. |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine. |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Pentazocine. |
| Promethazine | The risk or severity of adverse effects can be increased when Promethazine is combined with Pentazocine. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Pentazocine. |
| Ipratropium | The risk or severity of adverse effects can be increased when Ipratropium is combined with Pentazocine. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Pentazocine. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Pentazocine. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine. |
| Profenamine | The risk or severity of adverse effects can be increased when Profenamine is combined with Pentazocine. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine. |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pentazocine. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pentazocine. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Pentazocine. |